{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T01:22:48Z","timestamp":1791595368070,"version":"4.3.4"},"publisher-location":"Cham","reference-count":68,"publisher":"Springer Nature Switzerland","isbn-type":[{"value":"9783031261626","type":"print"},{"value":"9783031261633","type":"electronic"}],"license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023]]},"DOI":"10.1007\/978-3-031-26163-3_15","type":"book-chapter","created":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T08:03:29Z","timestamp":1682323409000},"page":"273-290","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Increase in Frequency of Myeloid-Derived Suppressor Cells in the Bone Marrow of Myeloproliferative Neoplasm: Potential Implications in Myelofibrosis"],"prefix":"10.1007","author":[{"given":"Sun\u010dica","family":"Kapor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanja","family":"Mom\u010dilovi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Slobodan","family":"Kapor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Slavko","family":"Mojsilovi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milica","family":"Radojkovi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milica","family":"Apostolovi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Branka","family":"Filipovi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirjana","family":"Goti\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladan","family":"\u010coki\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan F.","family":"Santibanez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,25]]},"reference":[{"key":"15_CR1","doi-asserted-by":"publisher","unstructured":"Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF et al. (2022 Jul) The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms. Leukemia 36(7):1703\u20131719. https:\/\/doi.org\/10.1038\/s41375-022-01613-1. Epub 2022 Jun 22. PMID: 35732831; PMCID: PMC9252913","DOI":"10.1038\/s41375-022-01613-1"},{"issue":"4","key":"15_CR2","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.3390\/ijms22041906.PMID:33672997;PMCID:PMC7918142","volume":"22","author":"V Nasillo","year":"2021","unstructured":"Nasillo V, Riva G, Paolini A, Forghieri F, Roncati L, Lusenti B et al (2021) Inflammatory microenvironment and specific T cells in myeloproliferative neoplasms: immunopathogenesis and novel immunotherapies. Int J Mol Sci 22(4):1906. https:\/\/doi.org\/10.3390\/ijms22041906.PMID:33672997;PMCID:PMC7918142","journal-title":"Int J Mol Sci"},{"key":"15_CR3","doi-asserted-by":"publisher","unstructured":"Tefferi A, Guglielmelli P, Larson DR, Finke C, Wassie EA, Pieri L et al. (2014 Oct 16) Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood 124(16):2507\u201313; quiz 2615. https:\/\/doi.org\/10.1182\/blood-2014-05-579136. Epub 2014 Jul 18. PMID: 25037629; PMCID: PMC4199952","DOI":"10.1182\/blood-2014-05-579136"},{"key":"15_CR4","doi-asserted-by":"publisher","unstructured":"Geyer HL, Dueck AC, Scherber RM, Mesa RA (2015) Impact of inflammation on myeloproliferative neoplasm symptom development. Med Inflamm 2015:284706. https:\/\/doi.org\/10.1155\/2015\/284706. Epub 2015 Oct 11. PMID: 26538823; PMCID: PMC4619953","DOI":"10.1155\/2015\/284706"},{"key":"15_CR5","doi-asserted-by":"publisher","unstructured":"Mendez Luque LF, Blackmon AL, Ramanathan G, Fleischman AG (2019 Jun) Key role of inflammation in myeloproliferative neoplasms: instigator of disease initiation, progression and symptoms. Curr Hematol Malig Rep 14(3):145\u2013153. https:\/\/doi.org\/10.1007\/s11899-019-00508-w. PMID: 31119475; PMCID: PMC7746200","DOI":"10.1007\/s11899-019-00508-w"},{"issue":"1","key":"15_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.cytox.2019.100005.PMID:33604548;PMCID:PMC7885877","volume":"1","author":"Y Wang","year":"2019","unstructured":"Wang Y, Zuo X (2019) Cytokines frequently implicated in myeloproliferative neoplasms. Cytokine X 1(1):100005. https:\/\/doi.org\/10.1016\/j.cytox.2019.100005.PMID:33604548;PMCID:PMC7885877","journal-title":"Cytokine X"},{"issue":"6","key":"15_CR7","doi-asserted-by":"publisher","first-page":"3206","DOI":"10.3390\/ijms23063206.PMID:35328626;PMCID:PMC8954909","volume":"23","author":"V Bhuria","year":"2022","unstructured":"Bhuria V, Baldauf CK, Schraven B, Fischer T (2022) Thromboinflammation in Myeloproliferative Neoplasms (MPN)-a puzzle still to be solved. Int J Mol Sci 23(6):3206. https:\/\/doi.org\/10.3390\/ijms23063206.PMID:35328626;PMCID:PMC8954909","journal-title":"Int J Mol Sci"},{"key":"15_CR8","doi-asserted-by":"publisher","unstructured":"Hermouet S, Bigot-Corbel E, Gardie B (2015) Pathogenesis of myeloproliferative neoplasms: role and mechanisms of chronic inflammation. Med Inflamm 2015:145293. https:\/\/doi.org\/10.1155\/2015\/145293. Epub 2015 Oct 11. PMID: 26538820; PMCID: PMC4619950","DOI":"10.1155\/2015\/145293"},{"issue":"6","key":"15_CR9","doi-asserted-by":"publisher","first-page":"660","DOI":"10.3324\/haematol.2015.141283.PMID:27252511;PMCID:PMC5013940","volume":"101","author":"AA Zahr","year":"2016","unstructured":"Zahr AA, Salama ME, Carreau N, Tremblay D, Verstovsek S, Mesa R, Hoffman R, Mascarenhas J (2016) Bone marrow fibrosis in myelofibrosis: pathogenesis, prognosis and targeted strategies. Haematologica 101(6):660\u2013671. https:\/\/doi.org\/10.3324\/haematol.2015.141283.PMID:27252511;PMCID:PMC5013940","journal-title":"Haematologica"},{"key":"15_CR10","doi-asserted-by":"publisher","unstructured":"Vukoti\u0107 M, Kapor S, Dragojevi\u0107 T, \u0110iki\u0107 D, Mitrovi\u0107 Ajti\u0107 O, Dikli\u0107 M et al. (2022 Mar) Inhibition of proinflammatory signaling impairs fibrosis of bone marrow mesenchymal stromal cells in myeloproliferative neoplasms. Exp Mol Med 54(3):273\u2013284. https:\/\/doi.org\/10.1038\/s12276-022-00742-y. Epub 2022 Mar 14. PMID: 35288649; PMCID: PMC8980093","DOI":"10.1038\/s12276-022-00742-y"},{"issue":"4","key":"15_CR11","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","volume":"7","author":"RL Levine","year":"2005","unstructured":"Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ et al (2005) Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7(4):387\u2013397. https:\/\/doi.org\/10.1016\/j.ccr.2005.03.023. PMID: 15837627","journal-title":"Cancer Cell"},{"key":"15_CR12","doi-asserted-by":"publisher","unstructured":"Wolf A, Eulenfeld R, G\u00e4bler K, Rolvering C, Haan S, Behrmann I et al. (2013 Jul 1) JAK2-V617F-induced MAPK activity is regulated by PI3K and acts synergistically with PI3K on the proliferation of JAK2-V617F-positive cells. JAKSTAT. 2(3):e24574. https:\/\/doi.org\/10.4161\/jkst.24574. Epub 2013 Apr 8. PMID: 24069558; PMCID: PMC3772110","DOI":"10.4161\/jkst.24574"},{"issue":"1","key":"15_CR13","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/s41392-021-00791-1.PMID:34824210;PMCID:PMC8617206","volume":"6","author":"X Hu","year":"2021","unstructured":"Hu X, Li J, Fu M, Zhao X, Wang W (2021) The JAK\/STAT signaling pathway: from bench to clinic. Signal Transduct Target Ther 6(1):402. https:\/\/doi.org\/10.1038\/s41392-021-00791-1.PMID:34824210;PMCID:PMC8617206","journal-title":"Signal Transduct Target Ther"},{"key":"15_CR14","doi-asserted-by":"publisher","unstructured":"Edahiro Y, Araki M, Komatsu N (2020 Aug) Mechanism underlying the development of myeloproliferative neoplasms through mutant calreticulin. Cancer Sci 111(8):2682\u20132688. https:\/\/doi.org\/10.1111\/cas.14503. Epub 2020 Jun 27. PMID: 32462673; PMCID: PMC7419020","DOI":"10.1111\/cas.14503"},{"issue":"9","key":"15_CR15","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.3390\/cells9092136.PMID:32967342;PMCID:PMC7564952","volume":"9","author":"E Masselli","year":"2020","unstructured":"Masselli E, Pozzi G, Gobbi G, Merighi S, Gessi S, Vitale M, Carubbi C (2020) Cytokine profiling in myeloproliferative neoplasms: overview on phenotype correlation, outcome prediction, and role of genetic variants. Cells 9(9):2136. https:\/\/doi.org\/10.3390\/cells9092136.PMID:32967342;PMCID:PMC7564952","journal-title":"Cells"},{"key":"15_CR16","doi-asserted-by":"publisher","unstructured":"Mojsilovic S, Mojsilovic SS, Bjelica S, Santibanez JF (2022 Jan) Transforming growth factor-beta1 and myeloid-derived suppressor cells: A cancerous partnership. Dev Dyn 251(1):105-124. https:\/\/doi.org\/10.1002\/dvdy.339. Epub 2021 Apr 8. PMID: 33797140","DOI":"10.1002\/dvdy.339"},{"issue":"12","key":"15_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.798320.PMID:34975496;PMCID:PMC8716856","volume":"16","author":"S Wang","year":"2021","unstructured":"Wang S, Tan Q, Hou Y, Dou H (2021) Emerging roles of myeloid-derived suppressor cells in diabetes. Front Pharmacol 16(12):798320. https:\/\/doi.org\/10.3389\/fphar.2021.798320.PMID:34975496;PMCID:PMC8716856","journal-title":"Front Pharmacol"},{"key":"15_CR18","doi-asserted-by":"publisher","unstructured":"Medina E, Hartl D (2018) Myeloid-Derived Suppressor Cells in Infection: A General Overview. J Innate Immun 10(5\u20136):407\u2013413. https:\/\/doi.org\/10.1159\/000489830. Epub 2018 Jun 26. PMID: 29945134; PMCID: PMC6784037","DOI":"10.1159\/000489830"},{"key":"15_CR19","doi-asserted-by":"publisher","unstructured":"Veglia F, Perego M, Gabrilovich D (2018 Feb) Myeloid-derived suppressor cells coming of age. Nat Immunol 19(2):108\u2013119. https:\/\/doi.org\/10.1038\/s41590-017-0022-x. Epub 2018 Jan 18. PMID: 29348500; PMCID: PMC5854158","DOI":"10.1038\/s41590-017-0022-x"},{"issue":"7","key":"15_CR20","doi-asserted-by":"publisher","first-page":"12150","DOI":"10.1038\/ncomms12150.PMID:27381735;PMCID:PMC4935811","volume":"6","author":"V Bronte","year":"2016","unstructured":"Bronte V, Brandau S, Chen SH, Colombo MP, Frey AB, Greten TF et al (2016) Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat Commun 6(7):12150. https:\/\/doi.org\/10.1038\/ncomms12150.PMID:27381735;PMCID:PMC4935811","journal-title":"Nat Commun"},{"issue":"1","key":"15_CR21","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000168.PMID:31723807;PMCID:PMC6745940","volume":"3","author":"N Bizymi","year":"2019","unstructured":"Bizymi N, Bjelica S, Kittang AO, Mojsilovic S, Velegraki M, Pontikoglou C et al (2019) Myeloid-derived suppressor cells in hematologic diseases: promising biomarkers and treatment targets. Hemasphere 3(1):e168. https:\/\/doi.org\/10.1097\/HS9.0000000000000168.PMID:31723807;PMCID:PMC6745940","journal-title":"Hemasphere"},{"key":"15_CR22","doi-asserted-by":"publisher","unstructured":"Veglia F, Sanseviero E, Gabrilovich DI (2021 Aug) Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity. Nat Rev Immunol 21(8):485\u2013498. https:\/\/doi.org\/10.1038\/s41577-020-00490-y. Epub 2021 Feb 1. PMID: 33526920; PMCID: PMC7849958","DOI":"10.1038\/s41577-020-00490-y"},{"issue":"6","key":"15_CR23","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.3390\/cancers13061362.PMID:33802925;PMCID:PMC8002694","volume":"13","author":"F Gondois-Rey","year":"2021","unstructured":"Gondois-Rey F, Paul M, Alcaraz F, Bourass S, Monnier J, Malissen N et al (2021) Identification of an immature subset of PMN-MDSC correlated to response to checkpoint inhibitor therapy in patients with metastatic melanoma. Cancers (Basel) 13(6):1362. https:\/\/doi.org\/10.3390\/cancers13061362.PMID:33802925;PMCID:PMC8002694","journal-title":"Cancers (Basel)"},{"key":"15_CR24","doi-asserted-by":"publisher","unstructured":"Cuenca AG, Delano MJ, Kelly-Scumpia KM, Moreno C, Scumpia PO, Laface DM et al. (2011 Mar\u2013Apr) A paradoxical role for myeloid-derived suppressor cells in sepsis and trauma. Mol Med 17(3\u20134):281\u201392. https:\/\/doi.org\/10.2119\/molmed.2010.00178. Epub 2010 Nov 12. PMID: 21085745; PMCID: PMC3060988.","DOI":"10.2119\/molmed.2010.00178"},{"issue":"9","key":"15_CR25","doi-asserted-by":"publisher","first-page":"284","DOI":"10.15698\/cst2019.09.197.PMID:31535085;PMCID:PMC6732213","volume":"3","author":"A Sica","year":"2019","unstructured":"Sica A, Guarneri V, Gennari A (2019) Myelopoiesis, metabolism and therapy: a crucial crossroads in cancer progression. Cell Stress 3(9):284\u2013294. https:\/\/doi.org\/10.15698\/cst2019.09.197.PMID:31535085;PMCID:PMC6732213","journal-title":"Cell Stress"},{"key":"15_CR26","doi-asserted-by":"publisher","unstructured":"Kumar V, Patel S, Tcyganov E, Gabrilovich DI (2016 Mar) The nature of myeloid-derived suppressor cells in the tumor microenvironment. Trends Immunol 37(3):208\u2013220. https:\/\/doi.org\/10.1016\/j.it.2016.01.004. Epub 2016 Feb 6. PMID: 26858199; PMCID: PMC4775398","DOI":"10.1016\/j.it.2016.01.004"},{"issue":"1","key":"15_CR27","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1158\/2326-6066.CIR-16-0297.PMID:28052991;PMCID:PMC5426480","volume":"5","author":"DI Gabrilovich","year":"2017","unstructured":"Gabrilovich DI (2017) Myeloid-derived suppressor cells. Cancer Immunol Res 5(1):3\u20138. https:\/\/doi.org\/10.1158\/2326-6066.CIR-16-0297.PMID:28052991;PMCID:PMC5426480","journal-title":"Cancer Immunol Res"},{"key":"15_CR28","doi-asserted-by":"publisher","unstructured":"Kalathil SG, Thanavala Y (2021 Mar) Importance of myeloid derived suppressor cells in cancer from a biomarker perspective. Cell Immunol 361:104280. https:\/\/doi.org\/10.1016\/j.cellimm.2020.104280. Epub 2020 Dec 31. PMID: 33445053; PMCID: PMC9204650","DOI":"10.1016\/j.cellimm.2020.104280"},{"issue":"4","key":"15_CR29","doi-asserted-by":"publisher","first-page":"617","DOI":"10.46497\/ArchRheumatol.2021.8632.PMID:35382360;PMCID:PMC8957769","volume":"36","author":"B\u0130 Co\u015fkun","year":"2021","unstructured":"Co\u015fkun B\u0130 (2021) The osteocyte as a director of bone metabolism. Arch Rheumatol. 36(4):617\u2013619. https:\/\/doi.org\/10.46497\/ArchRheumatol.2021.8632.PMID:35382360;PMCID:PMC8957769","journal-title":"Arch Rheumatol."},{"key":"15_CR30","doi-asserted-by":"publisher","unstructured":"Zanetti C, Krause DS (2020 Sep) Caught in the net: the extracellular matrix of the bone marrow in normal hematopoiesis and leukemia. Exp Hematol 89:13\u201325. https:\/\/doi.org\/10.1016\/j.exphem.2020.07.010. Epub 2020 Aug 2. PMID: 32755619","DOI":"10.1016\/j.exphem.2020.07.010"},{"issue":"1","key":"15_CR31","doi-asserted-by":"publisher","first-page":"122","DOI":"10.3390\/biom11010122.PMID:33477816;PMCID:PMC7832894","volume":"11","author":"M Spampinato","year":"2021","unstructured":"Spampinato M, Giallongo C, Romano A, Longhitano L, La Spina E, Avola R et al (2021) Focus on osteosclerotic progression in primary myelofibrosis. Biomolecules 11(1):122. https:\/\/doi.org\/10.3390\/biom11010122.PMID:33477816;PMCID:PMC7832894","journal-title":"Biomolecules"},{"issue":"8","key":"15_CR32","first-page":"1128","volume":"90","author":"J Thiele","year":"2005","unstructured":"Thiele J, Kvasnicka HM, Facchetti F, Franco V, van der Walt J, Orazi A (2005) European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica 90(8):1128\u20131132 PMID: 16079113","journal-title":"Haematologica"},{"issue":"11","key":"15_CR33","doi-asserted-by":"publisher","DOI":"10.1172\/JCI154092.PMID:35439167;PMCID:PMC9151699","volume":"132","author":"JC Yao","year":"2022","unstructured":"Yao JC, Oetjen KA, Wang T, Xu H, Abou-Ezzi G, Krambs JR, Uttarwar S, Duncavage EJ, Link DC (2022) TGF-\u03b2 signaling in myeloproliferative neoplasms contributes to myelofibrosis without disrupting the hematopoietic niche. J Clin Invest 132(11):e154092. https:\/\/doi.org\/10.1172\/JCI154092.PMID:35439167;PMCID:PMC9151699","journal-title":"J Clin Invest"},{"key":"15_CR34","doi-asserted-by":"publisher","unstructured":"Verstovsek S, Manshouri T, Pilling D, Bueso-Ramos CE, Newberry KJ, Prijic S et al. (2016 Aug 22) Role of neoplastic monocyte-derived fibrocytes in primary myelofibrosis. J Exp Med 213(9):1723\u201340. https:\/\/doi.org\/10.1084\/jem.20160283. Epub 2016 Aug 1. PMID: 27481130; PMCID: PMC4995084","DOI":"10.1084\/jem.20160283"},{"key":"15_CR35","doi-asserted-by":"publisher","unstructured":"Casacuberta-Serra S, Par\u00e9s M, Golbano A, Coves E, Espejo C, Barquinero J (2017 Jul) Myeloid-derived suppressor cells can be efficiently generated from human hematopoietic progenitors and peripheral blood monocytes. Immunol Cell Biol 95(6):538\u2013548. https:\/\/doi.org\/10.1038\/icb.2017.4. Epub 2017 Jan 21. PMID: 28108746","DOI":"10.1038\/icb.2017.4"},{"issue":"3","key":"15_CR36","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1111\/j.1582-4934.2011.01437.x.PMID:21895966;PMCID:PMC3822920","volume":"16","author":"Y Wang","year":"2012","unstructured":"Wang Y, Ma Y, Fang Y, Wu S, Liu L, Fu D, Shen X (2012) Regulatory T cell: a protection for tumour cells. J Cell Mol Med 16(3):425\u2013436. https:\/\/doi.org\/10.1111\/j.1582-4934.2011.01437.x.PMID:21895966;PMCID:PMC3822920","journal-title":"J Cell Mol Med"},{"key":"15_CR37","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.leukres.2016.02.004","volume":"43","author":"JC Wang","year":"2016","unstructured":"Wang JC, Kundra A, Andrei M, Baptiste S, Chen C, Wong C, Sindhu H (2016) Myeloid-derived suppressor cells in patients with myeloproliferative neoplasm. Leuk Res 43:39\u201343. https:\/\/doi.org\/10.1016\/j.leukres.2016.02.004. Epub 2016 Feb 16 PMID: 26943702","journal-title":"Leuk Res"},{"issue":"6","key":"15_CR38","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1158\/1078-0432.CCR-08-1332","volume":"15","author":"JS Ko","year":"2009","unstructured":"Ko JS, Zea AH, Rini BI, Ireland JL, Elson P, Cohen P et al (2009) Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res 15(6):2148\u20132157. https:\/\/doi.org\/10.1158\/1078-0432.CCR-08-1332. Epub 2009 Mar 10 PMID: 19276286","journal-title":"Clin Cancer Res"},{"issue":"11","key":"15_CR39","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.3390\/jpm11111048.PMID:34834400;PMCID:PMC8619969","volume":"11","author":"S Kapor","year":"2021","unstructured":"Kapor S, Vukoti\u0107 M, Suboti\u010dki T, \u0110iki\u0107 D, Mitrovi\u0107 Ajti\u0107 O, Radojkovi\u0107 M et al (2021) Hydroxyurea induces bone marrow mesenchymal stromal cells senescence and modifies cell functionality in vitro. J Pers Med 11(11):1048. https:\/\/doi.org\/10.3390\/jpm11111048.PMID:34834400;PMCID:PMC8619969","journal-title":"J Pers Med"},{"issue":"2","key":"15_CR40","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41408-018-0054-y.PMID:29426921;PMCID:PMC5807384","volume":"8","author":"T Barbui","year":"2018","unstructured":"Barbui T, Thiele J, Gisslinger H, Kvasnicka HM, Vannucchi AM, Guglielmelli P et al (2018) The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. Blood Cancer J 8(2):15. https:\/\/doi.org\/10.1038\/s41408-018-0054-y.PMID:29426921;PMCID:PMC5807384","journal-title":"Blood Cancer J"},{"issue":"20","key":"15_CR41","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM et al (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127(20):2391\u20132405. https:\/\/doi.org\/10.1182\/blood-2016-03-643544. Epub 2016 Apr 11 PMID: 27069254","journal-title":"Blood"},{"key":"15_CR42","doi-asserted-by":"publisher","unstructured":"Nazha A, Khoury JD, Rampal RK, Daver N (2015 Oct) Fibrogenesis in primary myelofibrosis: diagnostic, clinical, and therapeutic implications. Oncologist 20(10):1154\u20131160. https:\/\/doi.org\/10.1634\/theoncologist.2015-0094. Epub 2015 Aug 24. PMID: 26304912; PMCID: PMC4591957","DOI":"10.1634\/theoncologist.2015-0094"},{"issue":"Suppl 1","key":"15_CR43","doi-asserted-by":"publisher","first-page":"S21","DOI":"10.1186\/1755-1536-5-S1-S21.PMID:23259436;PMCID:PMC3368793","volume":"5","author":"H Kreipe","year":"2012","unstructured":"Kreipe H, B\u00fcsche G, Bock O, Hussein K (2012) Myelofibrosis: molecular and cell biological aspects. Fibrogenesis Tissue Repair 5(Suppl 1):S21. https:\/\/doi.org\/10.1186\/1755-1536-5-S1-S21.PMID:23259436;PMCID:PMC3368793","journal-title":"Fibrogenesis Tissue Repair"},{"issue":"1","key":"15_CR44","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/s12943-022-01657-y.PMID:36163047;PMCID:PMC9513992","volume":"21","author":"Y Wu","year":"2022","unstructured":"Wu Y, Yi M, Niu M, Mei Q, Wu K (2022) Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy. Mol Cancer 21(1):184. https:\/\/doi.org\/10.1186\/s12943-022-01657-y.PMID:36163047;PMCID:PMC9513992","journal-title":"Mol Cancer"},{"issue":"5","key":"15_CR45","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1097\/CCO.0000000000000662.PMID:32675593;PMCID:PMC7735379","volume":"32","author":"EG Gunes","year":"2020","unstructured":"Gunes EG, Rosen ST, Querfeld C (2020) The role of myeloid-derived suppressor cells in hematologic malignancies. Curr Opin Oncol 32(5):518\u2013526. https:\/\/doi.org\/10.1097\/CCO.0000000000000662.PMID:32675593;PMCID:PMC7735379","journal-title":"Curr Opin Oncol"},{"issue":"4","key":"15_CR46","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s11899-014-0227-0","volume":"9","author":"G Barosi","year":"2014","unstructured":"Barosi G (2014) An immune dysregulation in MPN. Curr Hematol Malig Rep 9(4):331\u2013339. https:\/\/doi.org\/10.1007\/s11899-014-0227-0. PMID: 25139710","journal-title":"Curr Hematol Malig Rep"},{"issue":"12","key":"15_CR47","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.638841.PMID:33679798;PMCID:PMC7928402","volume":"12","author":"N Tumino","year":"2021","unstructured":"Tumino N, Di Pace AL, Besi F, Quatrini L, Vacca P, Moretta L (2021) Interaction between MDSC and NK cells in solid and hematological malignancies: impact on HSCT. Front Immunol 12(12):638841. https:\/\/doi.org\/10.3389\/fimmu.2021.638841.PMID:33679798;PMCID:PMC7928402","journal-title":"Front Immunol"},{"issue":"9","key":"15_CR48","doi-asserted-by":"publisher","first-page":"603","DOI":"10.3389\/fonc.2019.00603.PMID:31334123;PMCID:PMC6617580","volume":"3","author":"V Garc\u00eda-Guti\u00e9rrez","year":"2019","unstructured":"Garc\u00eda-Guti\u00e9rrez V, Hern\u00e1ndez-Boluda JC (2019) Tyrosine kinase inhibitors available for chronic myeloid leukemia: efficacy and safety. Front Oncol 3(9):603. https:\/\/doi.org\/10.3389\/fonc.2019.00603.PMID:31334123;PMCID:PMC6617580","journal-title":"Front Oncol"},{"issue":"5","key":"15_CR49","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1158\/1535-7163.MCT-14-0849","volume":"14","author":"L Christiansson","year":"2015","unstructured":"Christiansson L, S\u00f6derlund S, Mangsbo S, Hjorth-Hansen H, H\u00f6glund M, Markev\u00e4rn B et al (2015) The tyrosine kinase inhibitors imatinib and dasatinib reduce myeloid suppressor cells and release effector lymphocyte responses. Mol Cancer Ther 14(5):1181\u20131191. https:\/\/doi.org\/10.1158\/1535-7163.MCT-14-0849. Epub 2015 Mar 11 PMID: 25761894","journal-title":"Mol Cancer Ther"},{"issue":"5","key":"15_CR50","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1007\/s12185-022-03335-7","volume":"115","author":"GG Loscocco","year":"2022","unstructured":"Loscocco GG, Vannucchi AM (2022) Role of JAK inhibitors in myeloproliferative neoplasms: current point of view and perspectives. Int J Hematol 115(5):626\u2013644. https:\/\/doi.org\/10.1007\/s12185-022-03335-7. Epub 2022 Mar 29 PMID: 35352288","journal-title":"Int J Hematol"},{"issue":"1","key":"15_CR51","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.beha.2019.02.004","volume":"32","author":"D Cuthbert","year":"2019","unstructured":"Cuthbert D, Stein BL (2019) Therapy-associated leukemic transformation in myeloproliferative neoplasms\u2014What do we know? Best Pract Res Clin Haematol 32(1):65\u201373. https:\/\/doi.org\/10.1016\/j.beha.2019.02.004. Epub 2019 Feb 8 PMID: 30927977","journal-title":"Best Pract Res Clin Haematol"},{"issue":"13","key":"15_CR52","doi-asserted-by":"publisher","first-page":"2788","DOI":"10.3390\/jcm10132788.PMID:34202907;PMCID:PMC8268878","volume":"10","author":"S Kapor","year":"2021","unstructured":"Kapor S, Santibanez JF (2021) Myeloid-derived suppressor cells and mesenchymal stem\/stromal cells in myeloid malignancies. J Clin Med 10(13):2788. https:\/\/doi.org\/10.3390\/jcm10132788.PMID:34202907;PMCID:PMC8268878","journal-title":"J Clin Med"},{"key":"15_CR53","doi-asserted-by":"publisher","unstructured":"Hyun SY, Na EJ, Jang JE, Chung H, Kim SJ, Kim JS, Kong JH, Shim KY, Lee JI, Min YH, Cheong JW (2020 Oct) Immunosuppressive role of CD11b+ CD33+ HLA-DR- myeloid-derived suppressor cells-like blast subpopulation in acute myeloid leukemia. Cancer Med 9(19):7007\u20137017. https:\/\/doi.org\/10.1002\/cam4.3360. Epub 2020 Aug 11. PMID: 32780544; PMCID: PMC7541151","DOI":"10.1002\/cam4.3360"},{"issue":"10","key":"15_CR54","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1182\/blood.2021015162","volume":"140","author":"RJ Stubbins","year":"2022","unstructured":"Stubbins RJ, Platzbecker U, Karsan A (2022) Inflammation and myeloid malignancy: quenching the flame. Blood 140(10):1067\u20131074. https:\/\/doi.org\/10.1182\/blood.2021015162. PMID: 35468199","journal-title":"Blood"},{"key":"15_CR55","doi-asserted-by":"publisher","unstructured":"Kleppe M, Kwak M, Koppikar P, Riester M, Keller M, Bastian L et al. (2015 Mar) JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response. Cancer Discov 5(3):316\u201331. https:\/\/doi.org\/10.1158\/2159-8290.CD-14-0736. Epub 2015 Jan 8. PMID: 25572172; PMCID: PMC4355105","DOI":"10.1158\/2159-8290.CD-14-0736"},{"issue":"5","key":"15_CR56","doi-asserted-by":"publisher","first-page":"107","DOI":"10.3389\/fonc.2015.00107.PMID:26029664;PMCID:PMC4432672","volume":"15","author":"C Giallongo","year":"2015","unstructured":"Giallongo C, Parrinello N, Brundo MV, Raccuia SA, Di Rosa M, La Cava P, Tibullo D (2015) Myeloid derived suppressor cells in chronic myeloid leukemia. Front Oncol 15(5):107. https:\/\/doi.org\/10.3389\/fonc.2015.00107.PMID:26029664;PMCID:PMC4432672","journal-title":"Front Oncol"},{"issue":"21","key":"15_CR57","doi-asserted-by":"publisher","first-page":"5531","DOI":"10.3390\/cancers13215531.PMID:34771693;PMCID:PMC8583143","volume":"13","author":"E Sabattini","year":"2021","unstructured":"Sabattini E, Pizzi M, Agostinelli C, Bertuzzi C, Sagramoso Sacchetti CA, Palandri F, Gianelli U (2021) Progression in Ph-chromosome-negative myeloproliferative neoplasms: an overview on pathologic issues and molecular determinants. Cancers (Basel) 13(21):5531. https:\/\/doi.org\/10.3390\/cancers13215531.PMID:34771693;PMCID:PMC8583143","journal-title":"Cancers (Basel)"},{"key":"15_CR58","unstructured":"Thiele J, Kvasnicka HM, Orazi A, Tefferi A, Birgegard G, Barbui T et al. (2017) WHO classification of tumours of haematopoietic and lymphoid tissues. IARC Geneva, Switzerland, pp 39\u201350"},{"issue":"9","key":"15_CR59","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1056\/NEJMc1708485","volume":"377","author":"JL Spivak","year":"2017","unstructured":"Spivak JL (2017) Myeloproliferative neoplasms. N Engl J Med 377(9):895\u2013896. https:\/\/doi.org\/10.1056\/NEJMc1708485. PMID: 28854086","journal-title":"N Engl J Med"},{"issue":"3","key":"15_CR60","doi-asserted-by":"publisher","first-page":"436","DOI":"10.3390\/jcm10030436.PMID:33498691;PMCID:PMC7866045","volume":"10","author":"F Mannelli","year":"2021","unstructured":"Mannelli F (2021) Acute myeloid leukemia evolving from myeloproliferative neoplasms: many sides of a challenging disease. J Clin Med 10(3):436. https:\/\/doi.org\/10.3390\/jcm10030436.PMID:33498691;PMCID:PMC7866045","journal-title":"J Clin Med"},{"issue":"3","key":"15_CR61","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.beha.2005.07.002","volume":"19","author":"H Chagraoui","year":"2006","unstructured":"Chagraoui H, Wendling F, Vainchenker W (2006) Pathogenesis of myelofibrosis with myeloid metaplasia: insight from mouse models. Best Pract Res Clin Haematol 19(3):399\u2013412. https:\/\/doi.org\/10.1016\/j.beha.2005.07.002. PMID: 16781480","journal-title":"Best Pract Res Clin Haematol"},{"issue":"21","key":"15_CR62","doi-asserted-by":"publisher","first-page":"5459","DOI":"10.3390\/ijms20215459.PMID:31683978;PMCID:PMC6862591","volume":"20","author":"GA Palumbo","year":"2019","unstructured":"Palumbo GA, Parrinello NL, Giallongo C, D\u2019Amico E, Zangh\u00ec A, Puglisi F et al (2019) Monocytic myeloid derived suppressor cells in hematological malignancies. Int J Mol Sci 20(21):5459. https:\/\/doi.org\/10.3390\/ijms20215459.PMID:31683978;PMCID:PMC6862591","journal-title":"Int J Mol Sci"},{"issue":"11","key":"15_CR63","doi-asserted-by":"publisher","DOI":"10.1172\/JCI154092.PMID:35439167;PMCID:PMC9151699","volume":"132","author":"JC Yao","year":"2022","unstructured":"Yao JC, Oetjen KA, Wang T, Xu H, Abou-Ezzi G, Krambs JR et al (2022) TGF-\u03b2 signaling in myeloproliferative neoplasms contributes to myelofibrosis without disrupting the hematopoietic niche. J Clin Invest 132(11):e154092. https:\/\/doi.org\/10.1172\/JCI154092.PMID:35439167;PMCID:PMC9151699","journal-title":"J Clin Invest"},{"issue":"3","key":"15_CR64","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3978\/j.issn.2306-9759.2016.02.03.PMID:27358897;PMCID:PMC4923632","volume":"26","author":"A Agarwal","year":"2016","unstructured":"Agarwal A, Morrone K, Bartenstein M, Zhao ZJ, Verma A, Goel S (2016) Bone marrow fibrosis in primary myelofibrosis: pathogenic mechanisms and the role of TGF-\u03b2. Stem Cell Investig 26(3):5. https:\/\/doi.org\/10.3978\/j.issn.2306-9759.2016.02.03.PMID:27358897;PMCID:PMC4923632","journal-title":"Stem Cell Investig"},{"issue":"6","key":"15_CR65","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/nrneph.2016.48","volume":"12","author":"XM Meng","year":"2016","unstructured":"Meng XM, Nikolic-Paterson DJ, Lan HY (2016) TGF-\u03b2: the master regulator of fibrosis. Nat Rev Nephrol 12(6):325\u2013338. https:\/\/doi.org\/10.1038\/nrneph.2016.48. Epub 2016 Apr 25 PMID: 27108839","journal-title":"Nat Rev Nephrol"},{"key":"15_CR66","doi-asserted-by":"publisher","unstructured":"Dong M, Blobe GC (2006 Jun 15) Role of transforming growth factor-beta in hematologic malignancies. Blood 107(12):4589\u201396. https:\/\/doi.org\/10.1182\/blood-2005-10-4169. Epub 2006 Feb 16. PMID: 16484590; PMCID: PMC1895802","DOI":"10.1182\/blood-2005-10-4169"},{"key":"15_CR67","doi-asserted-by":"publisher","unstructured":"Deng X, Li X, Guo X, Lu Y, Xie Y, Huang X et al. (2022 Jun) Myeloid-derived suppressor cells promote tumor growth and sorafenib resistance by inducing FGF1 upregulation and fibrosis. Neoplasia 28:100788. https:\/\/doi.org\/10.1016\/j.neo.2022.100788. Epub 2022 Apr 1. PMID: 35378464; PMCID: PMC8980488","DOI":"10.1016\/j.neo.2022.100788"},{"issue":"12","key":"15_CR68","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.698894","volume":"10","author":"Y Qiu","year":"2021","unstructured":"Qiu Y, Cao Y, Tu G, Li J, Su Y, Fang F et al (2021) Myeloid-derived suppressor cells alleviate renal fibrosis progression via regulation of CCL5-CCR5 axis. Front Immunol 10(12):698894. https:\/\/doi.org\/10.3389\/fimmu.2021.698894","journal-title":"Front Immunol"}],"container-title":["Advances in Experimental Medicine and Biology","Advances in Molecular Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-031-26163-3_15","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T08:06:43Z","timestamp":1682323603000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-3-031-26163-3_15"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"ISBN":["9783031261626","9783031261633"],"references-count":68,"URL":"https:\/\/doi.org\/10.1007\/978-3-031-26163-3_15","relation":{},"ISSN":["0065-2598","2214-8019"],"issn-type":[{"value":"0065-2598","type":"print"},{"value":"2214-8019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023]]},"assertion":[{"value":"25 April 2023","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}